載入中
Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services. The company's pipeline features several investigational compounds. Among these is Zunsemetinib, an MK2 inhibitor, being developed to treat moderate to severe cases of rheumatoid arthritis, psoriatic arthritis, and hidradenitis suppurativa. Another significant candidate is ATI-1777, a soft JAK 1/3 inhibitor, intended for the management of moderate to severe atopic dermatitis. Additionally, Aclaris is advancing ATI-2138, an ITK/TXK/JAK3 inhibitor, as a potential intervention for T cell-mediated autoimmune diseases; a Gut-Biased Program targeting inflammatory bowel disease; and ATI-2231, an MK2 inhibitor, for the treatment of pancreatic and metastatic breast cancer. Established in 2012, Aclaris Therapeutics, Inc. has its corporate headquarters situated in Wayne, Pennsylvania.
前收盤價
US$3.83
+US$0.04 · +1.06%
盤中時間採用ET。市場資料可能有所延遲。
Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services. The company's pipeline features several investigational compounds. Among these is Zunsemetinib, an MK2 inhibitor, being developed to treat moderate to severe cases of rheumatoid arthritis, psoriatic arthritis, and hidradenitis suppurativa. Another significant candidate is ATI-1777, a soft JAK 1/3 inhibitor, intended for the management of moderate to severe atopic dermatitis. Additionally, Aclaris is advancing ATI-2138, an ITK/TXK/JAK3 inhibitor, as a potential intervention for T cell-mediated autoimmune diseases; a Gut-Biased Program targeting inflammatory bowel disease; and ATI-2231, an MK2 inhibitor, for the treatment of pancreatic and metastatic breast cancer. Established in 2012, Aclaris Therapeutics, Inc. has its corporate headquarters situated in Wayne, Pennsylvania.
日內區間
目前US$3.83
52週區間
目前US$3.83
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 782.6萬 USD | 1872萬 USD | 3124.9萬 USD | 2975.2萬 USD | 676.1萬 USD |
| 銷貨成本 | 209.1萬 USD | 279.2萬 USD | 1808.1萬 USD | 1196萬 USD | 471.3萬 USD |
| 毛利 | 573.5萬 USD | 1592.8萬 USD | 1316.8萬 USD | 1779.2萬 USD | 204.8萬 USD |
| 研究與開發 | 5264.5萬 USD | 3358.6萬 USD | 9838.4萬 USD | 7781.3萬 USD | 4381.3萬 USD |
| 銷售、一般及管理費用 | 2197.2萬 USD | 2220.3萬 USD | 3109.8萬 USD | 2513.3萬 USD | 2361.9萬 USD |
| 營業費用 | 8211萬 USD | 1.58億 USD | 1.11億 USD | 1.08億 USD | 9177.1萬 USD |
| 利息收入 | 763.7萬 USD | 795.3萬 USD | — | — | — |
| 折舊和攤銷 | 45.4萬 USD | 80.7萬 USD | 86.3萬 USD | 79.7萬 USD | 92.3萬 USD |
| 營業利益 | −7637.5萬 USD | −1.42億 USD | −9735.7萬 USD | −8985.4萬 USD | −8972.3萬 USD |
| 淨利 | −6492.3萬 USD | −1.32億 USD | −8848.1萬 USD | −8690.8萬 USD | −9086.5萬 USD |
公司資料更新於 2026年10月11日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動，並非 GoAI 建議。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
